Drug intelligence / Profile preview

CTO0303-B

Development stage: Preclinical
Lead developer: Taejoon Pharmaceutical
Administration: Ophthalmic

Overview

CTO0303-B is an experimental ophthalmic drug formulation being evaluated as an eye drop for pediatric subjects. It is administered as one drop three times (every five minutes) a day. The specific active ingredient, mechanism of action, and therapeutic class are not disclosed in the available sources. The drug is currently under investigation in clinical trials comparing its efficacy and safety to other formulations such as CTO0303-C[1].

Beyond the preview

Go deeper on CTO0303-B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTO0303-B.

Explore the full profile